Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
Author(s)
Periselneris, J
Nwankwo, L
Schelenz, S
Shah, A
Armstrong-James, D
Type
Journal Article
Abstract
OBJECTIVES: Allergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment. PATIENTS AND METHODS: We evaluated Aspergillus-specific IgE and the use of therapeutic drug monitoring of triazoles in a retrospective analysis of 32 patients. RESULTS: There was a significant reduction in Aspergillus IgE with posaconazole but not with other triazoles (P = 0.026). Aspergillus IgE levels were inversely correlated with the therapeutic drug level of posaconazole. CONCLUSIONS: These data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.
Date Issued
2019-06-01
Date Acceptance
2019-01-29
Citation
Journal of Antimicrobial Chemotherapy, 2019, 74 (6), pp.1701-1703
ISSN
0305-7453
Publisher
Oxford University Press (OUP)
Start Page
1701
End Page
1703
Journal / Book Title
Journal of Antimicrobial Chemotherapy
Volume
74
Issue
6
Copyright Statement
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Sponsor
Wellcome Trust
Wellcome Trust
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/30805605
PII: 5364630
Grant Number
WTSA MMFI Clinical PhD Fellow
204566/Z/16/Z
Subjects
Microbiology
1115 Pharmacology and Pharmaceutical Sciences
0605 Microbiology
1108 Medical Microbiology
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2019-02-25